Yahoo Web Search

  1. Should Amgen Inc. (NASDAQ:AMGN) Be Part Of Your Dividend Portfolio?

    Simply Wall St. via Yahoo FinanceJul 04 12:25 PM

    Could Amgen Inc. (NASDAQ:AMGN) be an attractive dividend share to own for the long haul? See if the 20 Amgen analysts we track are forecasting continued growth with our free report on analyst estimates for the company.

  2. Amgen's Osteoporosis Drug Evenity Gets Adverse CHMP View

    Zacks via Yahoo FinanceJun 28 13:56 PM

    Amgen Inc. AMGN and Belgian partner UCB announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a negative opinion ...

  3. Amgen (AMGN) Gains But Lags Market: What You Should Know

    Zacks via Yahoo FinanceJun 28 21:45 PM

    Amgen (AMGN) closed the most recent trading day at $184.28, moving +0.14% from the previous trading session. This move lagged the S&P 500's daily gain of 0.58%. This has outpaced the ...

  4. Top Analyst Reports: Mastercard, Coca-Cola, Amgen & More

    Zacks via Yahoo FinanceJul 04 14:31 PM

    Today's Research Daily features new research reports on 16 major stocks, including Mastercard MA , Coca-Cola (KO) and Amgen (AMGN). These research reports have been hand-picked from roughly ...

  5. Pfizer, Inc. PFE announced that the FDA has granted approval to Zirabev, its biosimilar version of Roche’s RHHBY blockbuster cancer drug, Avastin for several types of cancer. This is ...

  6. NASDAQ: ADXS) Aerie Pharmaceuticals Inc (NASDAQ: AERI) Atara Biotherapeutics Inc (NASDAQ: ATRA) Evolent Health Inc (NYSE: EVH) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX) ...

  7. Amarin Corporation plc AMRN announced impressive preliminary second-quarter sales results, which led it to raise its total sales guidance for 2019. The company estimates second-quarter sales ...

  8. Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) (received fast track designation for its RNAi therapeutic for rare genetic liver disease associated with alpha-1 antitrypsin deficiency) Odonate ...

  9. Mirati Inks Deal with Novartis to Evaluate Tumor Candidate

    Zacks via Yahoo FinanceJul 10 21:53 PM

    Mirati Therapeutics, Inc. MRTX has inked a clinical collaboration agreement with Novartis AG (NVS) to evaluate the combination of the former's investigational KRAS G12C inhibitor, MRTX849 ...

  10. A judge in the United States District Court in the District of Columbia sentenced in support of Merck MRK, Eli Lilly LLY and Amgen AMGN determining that the Department of Health and Human ...

  1. Ads
    related to Amgen Inc